This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Biotech ETFs in Focus on String of Q1 Earnings Beats
by Sweta Jaiswal, FRM
Let's take a sneak peek at some ETFs having high exposure to some impactful biotechnological companies on the release of Q1 earnings results.
Novo Nordisk (NVO) Q1 Earnings and Revenues Miss Estimates
by Zacks Equity Research
Novo Nordisk's (NVO) earnings and sales miss estimates in the first quarter of 2019.
Gilead (GILD) Earnings Beat, Revenues Miss Estimates in Q1
by Zacks Equity Research
Biotech bigwig Gilead's (GILD) Q1 financial report is mixed with dismal sales and an earnings beat.
Gilead Sciences (GILD) Q1 Earnings Top Estimates
by Zacks Equity Research
Gilead (GILD) delivered earnings and revenue surprises of 8.64% and -0.49%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
Is a Beat in the Cards for Mallinckrodt (MNK) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Specialty Brands and other pipeline updates, when Mallinckrodt (MNK) reports Q1 results on May 7.
What's in the Cards for Novavax (NVAX) This Earnings Season?
by Zacks Equity Research
Novavax (NVAX) is likely to provide update on the path forward for its two lead vaccine candidates.
What's in the Cards for Sunesis (SNSS) This Earnings Season?
by Zacks Equity Research
Sunesis Pharmaceuticals' (SNSS) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, vecabrutinib.
AVEO Pharmaceuticals (AVEO) to Post Q1 Earnings: What's Up?
by Zacks Equity Research
During AVEO Pharmaceuticals' (AVEO) Q1 conference call, investor focus will be on its NDA submission for Fotivda in the United States pertaining to the treatment of advanced or metastatic RCC.
Incyte (INCY) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
While Incyte's (INCY) earnings and revenues beat estimates in Q1, Jakafi sales fall short of the same.
What's in the Cards for Zynerba (ZYNE) This Earnings Season?
by Zacks Equity Research
Zynerba Pharmaceuticals' (ZYNE) operating expenses are expected to be higher in the first quarter due to clinical studies on its lead pipeline candidate, Zygel.
What's in Store for ANI Pharmaceuticals (ANIP) Q1 Earnings?
by Zacks Equity Research
ANI Pharmaceuticals (ANIP) will provide updates on product launches, when it releases first-quarter 2019 results.
What's in the Cards for Bausch Health (BHC) Q1 Earnings?
by Zacks Equity Research
Investors are looking forward to the performance of Salix and Bausch + Lomb, and other pipeline updates, when Bausch (BHC) reports Q1 results on May 6.
Is a Beat in the Cards for Incyte (INCY) in Q1 Earnings?
by Zacks Equity Research
Incyte (INCY) is slated to report first-quarter results on Apr 30. Investors will primarily focus on Jakafi sales and pipeline updates.
What's in the Cards for Sarepta (SRPT) This Earnings Season?
by Zacks Equity Research
Sarepta Therapeutics' (SRPT) Exondys 51 likely to drive first-quarter sales.
Sangamo (SGMO) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
For Sangamo's (SGMO) Q1, investor focus will be on its gene therapy candidate, SB-525, currently under evaluation for hemophilia A. The company also boasts several other early-stage promising candidates in its pipeline.
Fibrocell (FCSC) Q1 Earnings: What's in Store for the Stock?
by Zacks Equity Research
For Fibrocell's (FCSC) Q1, investors will eye the company's progress with its gene therapy candidate, FCX-007, currently being developed for treating recessive dystrophic epidermolysis bullosa.
5 Drug/Biotech Stocks Poised to Beat Q1 Earnings Estimates
by Zacks Equity Research
So far, the going seems good for the drug/biotech sector this earnings season. Let us take a glance at a few other companies, which hold promise to beat on Q1 earnings.
Gilead Sciences (GILD) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Gilead Sciences (GILD) closed at $65.15 in the latest trading session, marking a +1.57% move from the prior day.
Will HIV Franchise Sales Drive Gilead's (GILD) Q1 Earnings?
by Zacks Equity Research
Investors are expected to focus on the HIV franchise and other pipeline updates, when Gilead (GILD) reports first-quarter results.
Is a Beat in Store for Glaxo (GSK) This Earnings Season?
by Zacks Equity Research
Strong sales of Glaxo's (GSK) Vaccines segment is likely to drive the top line in the first quarter.
Gilead Sciences (GILD) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Gilead (GILD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
GILD vs. ALKS: Which Stock Is the Better Value Option?
by Zacks Equity Research
GILD vs. ALKS: Which Stock Is the Better Value Option?
Will Biotech ETFs Continue to Rally in Q1 Earnings?
by Sweta Jaiswal, FRM
Here we study the possible impact of some major Q1 earnings releases on certain biotech ETFs .
What's in the Cards for Amarin (AMRN) This Earnings Season?
by Zacks Equity Research
Amarin's (AMRN) cardiovascular drug, Vascepa to drive sales in the first quarter.
Trevena (TRVN) to Post Q1 Earnings: What Awaits the Stock?
by Zacks Equity Research
During Trevena's (TRVN) first-quarter 2019 conference call, investor focus will be on the company's progress to support its development of the pain therapy ??? oliceridine injection.